Biotechnology · Healthcare
CEO, Board Member
2013-01-01–present
Equibles does not estimate personal net worth.
Get an email with a short summary when 4D Molecular Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get FDMT alertsDavid Kirn is recorded as Board Member at 4D Molecular Therapeutics, Inc. (FDMT) since January 1, 2013 and CEO at 4D Molecular Therapeutics, Inc. (FDMT). The newest filing on record that lists David Kirn as CEO and Board Member at 4D Molecular Therapeutics, Inc. (FDMT) is dated April 28, 2026. The proxy statement of 4D Molecular Therapeutics, Inc. reports total compensation of $2,051,343 for David Kirn in fiscal 2025, including a base salary of $667,252. Disclosed compensation is on record for 7 fiscal years. David Kirn has spoken on 5 investor events across 1 company, most recently for 4D Molecular Therapeutics, Inc. on September 14, 2026. 4D Molecular Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at 4D Molecular Therapeutics, Inc. includes David Kirn, M.D. (CEO), Ashoo Gupta (CFO), Kristian Humer (CFO and Chief Accounting Officer) and 7 others.
“So Dave Kern, founder and CEO, it's good to see you. Thanks for having us. Yeah, we're bringing next-generation gene therapy to large markets.”
“I'm happy to start with that, and Christian can fill the details in our catalysts that are coming up over the next 12 months. So first of all, 4DMT, we're a next-generation gene therapy company, platform company.”
“I think we're going without slides today, Great. So we're a next-generation AV gene therapy company with a lead product, 4150, for wet AMD and diabetic eye disease.”
“I appreciate the time to share with you an overview of 4D molecular therapeutics. So we'll walk through today how 4DMT, we believe, is well positioned to redefine genetic medicines for millions of patients worldwide.”
“So now we're going to deal with the lead product in our pulmonary franchise.”
2013-01-01–present
Last confirmed April 28, 2026
Start not stated–present
Last confirmed April 28, 2026
Biotechnology · Healthcare
CEO, Board Member
2013-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | 4D Molecular Therapeutics, Inc. (FDMT) | President and Chief Executive Officer | $667,252 | $2,051,343 |
| 2024 | 4D Molecular Therapeutics, Inc. (FDMT) | Chief Executive Officer | $662,780 | $1,009,004 |
| 2023 | 4D Molecular Therapeutics, Inc. (FDMT) | Chief Executive Officer | $596,640 | $10,286,808 |
| 2022 | 4D Molecular Therapeutics, Inc. (FDMT) | Chief Executive Officer | $585,720 | $3,287,970 |
| 2021 | 4D Molecular Therapeutics, Inc. (FDMT) | Chief Executive Officer | $570,000 | $5,200,825 |
| 2020 | 4D Molecular Therapeutics, Inc. (FDMT) | Chief Executive Officer | $451,189 | $701,533 |
| 2019 | 4D Molecular Therapeutics, Inc. (FDMT) | Chief Executive Officer | $430,000 | $554,300 |